High Grade Neuroendocrine Carcinoma, Any Site
2 clinical trials · Condition
◉ Watch High Grade Neuroendocrine Carcinoma, Any Site
| Record | Firm | Date |
|---|---|---|
| Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors (NCT05746208) | University of California, San Francisco | 2023-07-17 |
| Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma (NCT03901378) | Ochsner Health System | 2019-10-02 |
Track High Grade Neuroendocrine Carcinoma, Any Site automatically
Every clearance here is in the API, with alerts when new ones post.